Skip to content

Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism

Embolism and Thrombosis

Venous thromboembolism (VTE) can be the earliest sign of cancer. Identifying occult cancers at the time of VTE diagnosis may lead to significant improvement of patients' care. This is also an upmost issue for patients who want to know if an underlying cancer might have triggered the VTE.

An individual patient-level data meta-analysis (IPDMA) supports extensive screening strategies for occult cancer especially based on FDG PET/CT, and suggests that the best target population for cancer screening would be patients with unprovoked VTE older than 50 years of age (6.7% in patients aged 50 years or more vs. 1.0% in patients of less than 50 years (OR: 7.1, 95% CI: 3.1 to 16%).

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    50 and up

Critères de participation

Inclusion Criteria:

Patients aged 50 years or older with a new diagnosis of first unprovoked proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE) will be eligible to participate into the study.

Unprovoked VTE is defined as the absence of any of the following predisposing factors:

1. active malignancy (known malignancy, progressive and/or treated during the last 5 years) except for adequately treated basal or squamous cell carcinoma; Patients whose state of health suggests the presence of cancer at the time of diagnosis of VTE cannot be included in the protocol
2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower extremities;
3. recently bedridden for period of 3 or more days, or major surgery, within the previous 12 weeks requiring general or regional anaesthesia;
4. previous unprovoked VTE;
5. known thrombophilia (hereditary or acquired)

Exclusion Criteria:

Patients will be excluded from the study if they have any of the following criteria:

1. Refusal or inability to provide informed consent;
2. Hypersensitivity to 18F-FDG or any of the excipients according to the product monograph;
3. Unavailable to follow-up.
4. VTE while on anticoagulation (e.g apixaban, rivaroxaban, edoxaban, dabigatran, warfarin)

Lieu de l'étude

McMaster University
McMaster University
Hamilton, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Deborah Siegal

Sunnybrook Research Institute
Sunnybrook Research Institute
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Jean-Phillippe Galanaud

University of Manitoba
University of Manitoba
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Primary Contact

Ryan Zarychanski

Ottawa Hospital Research Institute
Ottawa Hospital Research Institute
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

Grégoire LE GAL

Backup Contact

Marc CARRIER

[email protected]
Primary Contact

Aurélien DELLUC

[email protected]
McGill University Health Centre
McGill University Health Centre
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Susan Solymoss

London Health Sciences Centre
London Health Sciences Centre
London, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Alejandro Lazno-Langner

University Health Network
University Health Network
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Backup Contact

Jameel Abdulrehman

Primary Contact

Erik Yeo

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Leslie Skeith

Hopital Montfort
Hopital Montfort
Ottawa, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Gregoire Le Gal

Jewish General Hospital
Jewish General Hospital
Montréal, Quebec
Canada

Contactez l'équipe d'étude

Primary Contact

Vicky Tagalakis

Étude parrainée par
University Hospital, Brest
Participants recherchés
Plus d'informations
ID de l'étude: NCT04304651